

Esophageal GIST

Supplemental Table 1. Overview of patient's characteristics in detail

Sex/age (L)	clinical symptoms				diagnostic				pathology			treatment & outcome					
	Inc	DP	WL	BL	EGD	FNA	ES	EUS	CT	Loc	Size	MR	CM	Surg	TKI	FU	Outcome
f/67 (1)	+	-	-	-	-	-	+	-	+	L	3.0	< 5/50	ND	EN	-	ND	ND
m/53 (2)	-	+	+	-	-	-	-	-	+	L	13.0	5-10/50	ND	-	+	ND	ND
f/74 (3)	-	+	-	-	+	+	-	-	+	M-L	12.0	ND	Sp	TEE	-	24	NoRec
f/54 (4)	+	-	-	-	-	-	-	-	+	L	11.0	2-3/10	Sp	TEE	+	79	Rec
m/74 (5)	+	-	-	-	+	-	-	-	+	ND	0.2	4/50	ND	TEE	-	ND	ND
m/62 (6)	+	-	-	-	+	-	-	-	+	L	6.8	6/50	ND	TEE	-	12	NoRec
f/58 (7)	-	-	-	-	-	-	-	-	+	L	> 10.0	5/50	ND	TEE	ND	ND	ND
m/21 (8)	-	+	-	-	+	-	-	-	+	M-L	4.8	0/50	Sp	EN	-	18	NoRec
m/36 (8)	-	+	-	-	-	-	-	+	+	L	6.5	0/50	Sp	EN	-	24	NoRec
m/69 (8)	-	+	+	-	+	+	-	-	+	L	6.0	> 50/50	Sp	TEE	+	12	Rec
f/66 (9)	-	-	-	+	-	-	-	+	+	L	3.0	< 1/10	ND	EN	-	ND	ND
m/57 (10)	-	ND	ND	ND	-	-	-	-	+	M + L	2.8 + 3.8	ND	ND	-	+	19	NoRec , SD
m/61 (11)	-	+	-	-	-	+	+	-	-	L	7.7	3/50	Sp	-	+	2	NoRec, SD
m/34 (12)	-	-	+	-	+	-	-	+	+	L	5.2	ND	ND	TEE	-	12	DOD
m/57 (13)	-	+	+	-	+	-	-	-	+	L	12.7	ND	Mix	TEE	-	3	Rec
m/75 (14)	-	-	-	+	+	-	-	+	+	L	14.0	1/10	ND	TEE	-	ND	ND
m/59 (15)	+	-	-	-	+	-	-	+	+	L	13.5	2/50	ND	TEE	-	12	NoRec
m/46 (16)	-	+	+	-	-	-	-	-	-	M	8.5	0/50	Sp	EN	-	14	NoRec
m/71 (17)	-	+	-	-	-	+	-	+	-	M	5.3	ND	ND	TEE	-	9	NoRec
m/57 (18)	-	+	-	+	+	-	-	-	-	L	16.0	30/50	Sp	TEE	-	60	Rec, DOD (i1)
m/57 (18)	-	-	-	+	+	-	-	-	-	L	11.0	25/50	Sp	TEE	-	58	Rec, DOD
m/49 (18)	+	-	-	-	+	-	-	-	-	L	3.0	0/50	Sp	EN	-	202	DDD
f/58 (18)	-	+	-	-	-	-	-	-	-	L	12.0	16/50	Ep	TEE	-	28	Rec, DOD (i2)
f/71 (18)	-	+	-	-	+	-	-	-	-	L	9.0	< 5/50	Sp	TEE	-	102	NED
m/56 (18)	-	+	-	-	+	-	-	-	-	L	15.0	22/50	Sp	TEE	-	63	Rec, DOD
m/52 (18)	+	-	-	-	+	-	-	-	-	L	4.5	< 5/50	Sp	EN	-	14	NED
f/64 (18)	-	+	-	-	+	-	-	-	-	L	7.5	0/50	Sp	EN	-	14	NED
f/74 (19)	-	-	-	-	+	+	-	+	-	L	12.5	30/50	Sp	EN	+	49	Rec, AWD (i3)
m/60 (19)	+	-	-	-	+	+	-	+	-	L	5.5	8/50	Ep	EN	-	41	Rec, NED (i4)
m/60 (19)	-	+	-	+	+	+	-	+	-	L	8.2	8/50	Mix	EN	-	26	NED
f/75 (19)	+	-	-	-	+	+	-	+	-	L	7.2	5/50	Sp	EN	-	17	NED
m/61 (20)	ND	ND	ND	ND	ND	ND	ND	ND	ND	L	2.6	10/50	Sp	ND	-	14	DDD (i5)
m/54 (20)	+	-	-	-	ND	ND	ND	ND	ND	L	3.5	2/50	Sp	ND	-	55	NED
m/50 (20)	+	-	-	-	ND	ND	ND	ND	ND	L	4.0	6/50	Sp	ND	-	106	NED
m/49 (20)	-	+	+	-	ND	ND	ND	ND	ND	L	4.5	0/50	Sp	ND	-	176	NED
m/56 (20)	-	+	-	-	ND	ND	ND	ND	ND	L	5.0	14/50	Sp	ND	-	20	DOD (i6)

Esophageal GIST

f/66 (20)	-	+	-	-	ND	ND	ND	ND	L	6.0	15/50	Sp	ND	-	62	NED
m/65 (20)	-	-	-	+	ND	ND	ND	ND	L	7.0	1/50	Ep	ND	-	2	DUC
m/55 (20)	-	+	-	-	ND	ND	ND	ND	L	8.0	26/50	Sp	ND	-	140	NED
f/58 (20)	-	+	+	-	ND	ND	ND	ND	L	8.5	59/50	Sp	ND	-	ND	ND
m/69 (20)	-	+	-	-	ND	ND	ND	ND	L	9.0	20/50	Sp	ND	-	27	DOD
m/63 (20)	-	+	-	-	ND	ND	ND	ND	L	10.0	79/50	Sp	ND	-	29	DOD
m/52 (20)	-	+	+	-	ND	ND	ND	ND	L	11.0	21/50	Sp	ND	-	54	DOD (i7)
f/66 (20)	-	-	-	-	ND	ND	ND	ND	L	15.0	16/50	Ep	ND	-	46	DOD (i8)
f/68 (20)	-	-	-	-	ND	ND	ND	ND	L	17.0	28/50	Ep	ND	-	49	DOD
f/70 (20)	-	-	-	-	ND	ND	ND	ND	L	25.0	5/50	Sp	ND	-	18	DOD
m/68 (20)	ND	L	ND	15/50	Ep	ND	-	22	DOD							
m/75 (20)	ND	L	ND	64/50	Sp	ND	-	37	DOD							
f/77	-	+	+	-	-	+	+	-	ND	9.0	ND	Sp	TEE	-	73	Rec/DOD
f/47	ND	1.5	ND	ND	ND	ND	ND	ND								
m/68	-	+	+	-	-	+	-	+	L	6.0	ND	Sp	TEE	-	ND	ND
f/37	-	-	-	-	ND	ND	ND	ND	ND	1.8	1/50	Sp	EN	-	119	NoRec
f/63	-	+	-	-	ND	ND	ND	ND	L	5.0	1/50	Sp	EN	-	55	NoRec
m/88	ND	3/50	Sp	ND	ND	ND	ND									
m/62	+	-	-	-	-	-	-	-	L	0.6	0/50	Sp	TEE	-	8	NoRec

+/‐: yes/no; AWD-alive with disease; BL-bleeding (gastrointestinal bleeding, hemoptysis, melena); CM-cell morphology; CT-(PET)CT; DDD-died of different disease; DOD-died of disease; DP-dysphagia; DUC-died of unknown cause; EGD-esophagogastroduodenoscopy; EN-thoracotomy, enucleation with excision of surrounding muscle (no mucosal excision); Ep-epitheloid; ES-endoscopy; EUS-endoscopic ultrasound; FNA-fine needle aspiration; FU-follow up (months); Inc-incidental; (L)-Literature; Loc-localisation-upper/middle/lower third of esophagus; Mix-mixed; MR-mitotic rate (x/x HPF); NED-no evidence of disease; ND-no data; NoRec-norecurrence; Rec-recurrence/metastasis; SD-stable disease; Size-size (cm); Sp-spindle; Surg-surgery; TEE-thoracotomy, esophagectomy, esophagogastrostomy; TKI-tyrosine kinase inhibitor; WL-weight loss. Additional information: i1-liver metastases after 30 months; i2-liver metastases after 4 months; i3-recurrence after 36 months; i4-recurrence after 19 months, therefore TEE, now NED; i5-cerebrovascular incident; i6-liver metastases at surgery; i7-lung metastases; i8-lung metastases. Literature: (1)-Yamada/2011 ¹; (2)-Ozan/2010 ²; (3)-Kaida/2010 ³; (4)-Hamada/2010 ⁴; (5)-Spinelli/2008 ⁵; (6)-Sakai/2008 ⁶; (7)-Papaspypros/2008 ⁷; (8)-Fang/2007 ⁸; (9)-Portale/2007 ⁹; (10)-Graham/2007 ¹⁰; (11)-Al-Salam/2006 ¹¹; (12)-Axel/2005 ¹²; (13)-Padula/2005 ¹³; (14)-Manu/2005 ¹⁴; (15)-Gouveia/2005 ¹⁵; (16)-Ertem/2004 ¹⁶; (17)-Iijima/2002 ¹⁷; (18)-Jiang/2010 ¹⁸; (19)-Blum/2007 ¹⁹; (20)-Miettinen/2000 ²⁰. Esophageal GIST patients: Green: case reports from the literature; Blue: case series from the literature; Yellow: patients extracted from Ulmer GIST registry.